NASDAQ : BMRN
BioMarin Pharmaceutical Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 58.51 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 11.33B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 11.33B |
| Enterprise Value | 14.65B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 193.57M |
| Shares Outstanding | 193.57M |
| Shares Change (YoY) | +0.61% |
| Shares Change (QoQ) | -1.62% |
| Owned by Insiders (%) | 0.40% |
| Owned by Institutions (%) | 102.47% |
| Float | 192.63M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 154.39 |
| Forward PE | 12.88 |
| PS Ratio | 3.32 |
| Forward PS | 2.63 |
| PB Ratio | 1.79 |
| P/TBV Ratio | 14.40 |
| P/FCF Ratio | 15.34 |
| P/OCF Ratio | 13.21 |
| PEG Ratio | 0.44 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 200.82 |
| EV / Sales | 4.30 |
| EV / EBITDA | 22.71 |
| EV / EBIT | 29.32 |
| EV / FCF | 19.85 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.39 |
| Quick Ratio | 1.16 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | 6.41 |
| Debt / FCF | 5.69 |
| Interest Coverage | 5.98 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 1.18% |
| Return on Assets (ROA) | 3.26% |
| Return on Invested Capital (ROIC) | 3.24% |
| Return on Capital Employed (ROCE) | 4.97% |
| Weighted Average Cost of Capital (WACC) | 4.23% |
| Revenue Per Employee | $1.06M |
| Profits Per Employee | $22,655 |
| Employee Count | 3,221 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 1.07 |
Taxes
| Measure | Value |
|---|
| Income Tax | 76.14M |
| Effective Tax Rate | 51.06% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.22 |
| 52-Week Price Change | +12.82% |
| 50-Day Moving Average | 60.62 |
| 200-Day Moving Average | 58.44 |
| Relative Strength Index (RSI) | 54.52 |
| Average Volume (20 Days) | 2,529,890 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 12.05M |
| Short Previous Month | 11.52M |
| Short % of Shares Out | 6.23% |
| Short % of Float | 6.26% |
| Short Ratio (days to cover) | 5.25 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 3.41B |
| Gross Profit | 1.74B |
| Operating Income | 499.75M |
| Pretax Income | 149.11M |
| Net Income | 72.97M |
| EBITDA | 645.32M |
| EBIT | 499.75M |
| Earnings Per Share (EPS) | $0.38 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 874.01M |
| Total Debt | 4.20B |
| Net Cash | -3.33B |
| Net Cash Per Share | -$17.19 |
| Equity (Book Value) | 6.32B |
| Book Value Per Share | 32.66 |
| Working Capital | 2.31B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 857.09M |
| Capital Expenditures | -118.91M |
| Depreciation & Amortization | 145.57M |
| Net Borrowing | 3.65B |
| Free Cash Flow | 738.18M |
| FCF Per Share | $3.81 |
Margins
| Measure | Value |
|---|
| Gross Margin | 50.97% |
| Operating Margin | 14.67% |
| Pretax Margin | 4.38% |
| Profit Margin | 2.14% |
| EBITDA Margin | 18.94% |
| EBIT Margin | 14.67% |
| FCF Margin | 21.67% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.61% |
| Shareholder Yield | -0.61% |
| Earnings Yield | 0.65% |
| FCF Yield | 6.52% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $91.56 |
| Price Target Difference | 56.49% |
| Analyst Consensus | Buy |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | 14.77% |
| EPS Growth Forecast (3Y) | 34.44% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.9 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |